Other
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Pfizer Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net remained flat by 0.0% to $3.00M in Q1 2026 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
Changes reflect new debt issuances or the refinancing of existing debt, impacting the effective interest rate of the company's obligations.
Detailed definition
The net balance of unamortized discounts, premiums, and issuance costs associated with debt instruments. These amounts a...
Peer comparison
Standard accounting adjustment for all companies with significant long-term debt structures.
Metric ID:
other_debt_instrument_unamortized_discount_premium_and_d_fde92fHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $3.00M | $3.00M |
| QoQ Change | — | +0.0% |
Range$3.00M – $3.00M
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at Other Companies
Frequently Asked Questions
- What is Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net?
- Pfizer (PFE) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $3.00M in Q1 2026.
- What does debt instrument, unamortized discount (premium) and debt issuance costs, net mean?
- The remaining portion of debt issuance costs or price adjustments that will be recognized as interest expense over time.